Research

*June  2024* In a recent study led by Suresh Ramalingam, MD, executive director of Winship Cancer Institute of Emory University, a new drug has shown remarkable promise in treating patients with a specific type of advanced lung cancer. Osimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the…

*May 2024* Key Takeaways: This combo is a promising treatment for patients with brain mets and/or leptomeningeal disease (LM) after first-line treatment for clinical meaningful rate of time on treatment and radiographic response: Patients with brain mets (PFS=5.9 months; OS=17.9 months) Patients with LM (PFS=8.3 months; OS=14.4 months); RAS/RAF/MAPK pathway…

*May 2024* Question  Among patients with non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant who experienced resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, does the addition of ivonescimab (a bispecific antibody targeting programmed cell death 1 protein and vascular endothelial growth factor) to chemotherapy improve progression-free…

*June 2024* This is an excellent presentation at ASCO 2024 by Dr. Jordi Remon Masip on treatment at time of resistance to EGFR TKIs. Those of you wanting to know what the latest is in options after progression on Tagrisso should look at the slide deck of his presentation here.

*June 2024* Purpose Leptomeningeal metastases (LMs) exhibit a high incidence in patients with epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC) post-treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib in patients with…

*June 2024* Keypoints:  A randomized comparative effectiveness trial confirmed that early palliative care delivered through video is just as effective as in-person visits on maintaining quality of life in patients with advanced lung cancer. At 24 weeks, quality of life as assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L)…

*May 2024* Key Takeaways: In the CHRYSALIS-2 study, amivantamab plus lazertinib demonstrated significant antitumor activity, including a 51% objective response rate and durable responses, in patients with atypical EGFR-mutated advanced NSCLC, regardless of prior treatment with afatinib. In the CHRYSALIS-2 study's Cohort C, evaluating amivantamab (ami) plus lazertinib (laz) in atypical…

*May 2024* Key takeaway: Amivantamab  combined with lazertinib significantly improved PFSl compared to osimertinib  in treatment-naïve patients with EGFR-mutant advanced non-small cell lung cancer, including those with high-risk features, establishing it as a promising new standard of care. Amivantamab (ami), an EGFR-MET bispecific antibody with immune cell-directing activity, combined with lazertinib…

*May 2024* Key Points: In patients with refractory EGFR-mutated advanced non–small cell lung cancer (NSCLC), subcutaneous amivantamab plus lazertinib was noninferior to intravenous (IV) amivantamab, as assessed by pharmacokinetics and objective response rate (ORR). Administration time was reduced from 2 to 5 hours with IV amivantamab to less than 5 minutes…

*May 2024* As targeted therapy gets more precise, the treatment paradigms shift, particularly for patients with non–small cell lung cancer (NSCLC). This patient population has seen substantial changes in standard of care as more nuance is added to the understanding of how resistance and mutations within the tumor are targeted.…